Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $48.09 and last traded at $46.95, with a volume of 294367 shares. The stock had previously closed at $48.11.
Gemini Therapeutics Trading Down 2.4 %
The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -48.11 and a beta of -0.12. The company has a 50 day moving average of $47.11 and a 200 day moving average of $42.90.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- The Average 401k Balance by Age Explained
- How is Compound Interest Calculated?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What does consumer price index measure?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
